Aprea Therapeutics (NASDAQ:APRE) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Aprea Therapeutics (NASDAQ:APRE) from a strong sell rating to a hold rating in a research report released on Monday morning,Zacks.com reports.

Several other research analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $4.00 target price (down from $5.00) on shares of Aprea Therapeutics in a report on Thursday, January 29th. Finally, Wedbush reduced their target price on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.50.

Aprea Therapeutics Price Performance

NASDAQ APRE opened at $0.60 on Monday. The company’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $1.22. Aprea Therapeutics has a 12 month low of $0.55 and a 12 month high of $3.72. The company has a market capitalization of $4.19 million, a P/E ratio of -0.28 and a beta of 1.48.

Insiders Place Their Bets

In other Aprea Therapeutics news, Director Marc Duey bought 21,459 shares of Aprea Therapeutics stock in a transaction dated Wednesday, December 10th. The stock was bought at an average price of $1.17 per share, for a total transaction of $25,107.03. Following the completion of the acquisition, the director directly owned 256,155 shares of the company’s stock, valued at approximately $299,701.35. This trade represents a 9.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 13.63% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. DRW Securities LLC acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned 1.73% of Aprea Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.